Amlodipine / Atorvastatin Online


Buy Caduet (Amlodipine Besylate, Atorvastatin Calcium) cardiovascular medication
Cheap qualitative Amlodipine with Atorvastatin 2.5/10 mg, 5/10 mg tablets online



HOW AND WHERE TO BUY CADUET (AMLODIPINE, ATORVASTATIN) 2.5/10 MG, 5/10 MG TABLETS OR CAPSULES ONLINE:


GENERIC DRUGS SHOP

Lowest prices
Good quality
from $1.00 per pill
15% discount coupon: qRr3ZyvhPv



MEDICINES STORE

Low prices
High quality
from $1.38 per pill
5% discount coupon: MSD5



PHARMA SHOP

Average prices
Best quality
from $1.86 per pill
10% discount coupon: hf-5478


For more offers please visit
PHARMA DOCTOR: AMLODIPINE, ATORVASTATIN



CADUET (AMLODIPINE BESYLATE, ATORVASTATIN CALCIUM) TABLETS: PRECAUTIONS

Hypotension

Symptomatic hypotension is possible, particularly in patients with severe aortic stenosis. Because of the gradual onset of action, acute hypotension is unlikely.

Beta-Blocker Withdrawal

The amlodipine component of Caduet is not a beta-blocker and therefore gives no protection against the dangers of abrupt beta-blocker withdrawal; any such withdrawal should be by gradual reduction of the dose of beta-blocker.

Endocrine Function

Statins, such as the atorvastatin component of Caduet interfere with cholesterol synthesis and theoretically might blunt adrenal and/or gonadal steroid production. Clinical studies have shown that atorvastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve. The effects of statins on male fertility have not been studied in adequate numbers of patients. The effects, if any, on the pituitary-gonadal axis in premenopausal women are unknown. Use caution when administering a statin with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.

CNS Toxicity

Atorvastatin

Brain hemorrhage was seen in a female dog treated with atorvastatin calcium (a component of Caduet) for 3 months at a dose equivalent to 120 mg atorvastatin/kg/day. Brain hemorrhage and optic nerve vacuolation were seen in another female dog that was sacrificed in moribund condition after 11 weeks of escalating doses of atorvastatin calcium equivalent to up to 280 mg atorvastatin/kg/day. The 120 mg/kg dose of atorvastatin resulted in a systemic exposure approximately 16 times the human plasma area-under-thecurve (AUC, 0-24 hours) based on the maximum human dose of 80 mg/day. A single tonic convulsion was seen in each of 2 male dogs (one treated with atorvastatin calcium at a dose equivalent to 10 mg atorvastatin/kg/day and one at a dose equivalent to 120 mg atorvastatin/kg/day) in a 2-year study. No CNS lesions have been observed in mice after chronic treatment for up to 2 years at doses of atorvastatin calcium equivalent to up to 400 mg atorvastatin/kg/day or in rats at doses equivalent to up to 100 mg atorvastatin/kg/day. These doses were 6 to 11 times (mouse) and 8 to 16 times (rat) the human AUC (0-24) based on the maximum recommended human dose of 80 mg atorvastatin/day.

CNS vascular lesions, characterized by perivascular hemorrhages, edema, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with other statins. A chemically similar drug in this class produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose.

Use in Patients with Recent Stroke or TIA

Atorvastatin

In a post-hoc analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study where atorvastatin 80 mg vs. placebo was administered in 4,731 subjects without CHD who had a stroke or TIA within the preceding 6 months, a higher incidence of hemorrhagic stroke was seen in the atorvastatin 80 mg group compared to placebo (55, 2.3% atorvastatin vs. 33, 1.4% placebo; HR: 1.68, 95% CI: 1.09, 2.59; p=0.0168). The incidence of fatal hemorrhagic stroke was similar across treatment groups (17 vs. 18 for the atorvastatin and placebo groups, respectively). The incidence of nonfatal hemorrhagic stroke was significantly higher in the atorvastatin group (38, 1.6%) as compared to the placebo group (16, 0.7%). Some baseline characteristics, including hemorrhagic and lacunar stroke on study entry, were associated with a higher incidence of hemorrhagic stroke in the atorvastatin group.

Information for Patients

Because of the risk of myopathy with statins, the drug class to which the atorvastatin component of Caduet belongs, advise patients to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.

Recent posts:

  • Purchase Caduet (Amlodipine, Atorvastatin) Online
  • Caduet prescribing information



    Copyright © 2016-2019 Amlodipine-Atorvastatin.2ordermeds.org, a division of Pharma-Doctor.com pharmaceutical network.

    Home Page | Privacy Policy | Cookies Policy | Terms of Service | Contact Us